Research news
Researchers in America have developed an experimental drug, similar to compounds used to treat diabetes, that slows the progression of Parkinson's in a mouse model of the condition.
Researchers have discovered that nicotinamide riboside, a form of vitamin B3, may boost energy in nerve cells and help prevent them being lost in Parkinson's.
Further analysis of the results from a recent clinical trial of the type 2 diabetes drug exenatide in people with Parkinson's has revealed encouraging signs of a positive effect on mood.
The trial will test whether drug treatment with a commonly prescribed dementia drug can improve balance and walking and help to prevent falls in people with Parkinson's.
We are pleased to announce that a Parkinson's research project has been awarded the inaugural BenevolentAI Award. The project will use an artificial intelligence platform’s capabilities to reason, deduce and suggest entirely new treatments for Parkinson’s.
An international team has developed a cutting-edge technique, enabling human brain tissue to be studied in 3D.
New international research suggests that too much calcium inside brain cells may trigger a chain reaction that leads to Parkinson's.
We're partnering with US company Neurolixis to accelerate the development of a drug that could prevent dyskinesia, a debilitating side effect of Parkinson's medication.
A study, featured in the Daily Mail, suggests a link between certain types of flu and risk of Parkinson's.
New figures from Parkinson's UK show that more than 12,000 Scots are now living with Parkinson's, and numbers are continuing to rise.